JPRN-jRCT2080220868未知2 期
A phase II dose-ranging study of SYR-472
适应症
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.The subject is an outpatient during the screening period.
- •2.The subject signs a written, informed consent form prior to the initiation of any study procedure., etc.
排除标准
- •1.The subject with serious cardiac disease, cerebrovascular disorder, or serious pancreatic or hematological disease.
- •2.The subject who is considered ineligible to participate in the study by the investigator or subinvestigator. etc.
研究者
相似试验
已完成
3 期
A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 DiabetesType 2 Diabetes MellitusNCT02324569Takeda240
已完成
2 期
Efficacy of SYR-472 in Subjects With Type 2 Diabetes MellitusDiabetes MellitusNCT00653185Takeda369
未知
3 期
Double-blind comparative study of SYR-472Diabetes mellitusJPRN-jRCT2080221797TAKEDA PHARMACEUTICAL COMPANY LTD.
已完成
2 期
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes MellitusDiabetes MellitusNCT00760344Takeda386
进行中（未招募）
1 期
Study of SAR439859 versus letrozole in ER positive, HER2 negative pre-operative post-menopausal primary breast cancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)CancerEUCTR2019-002015-26-ESSANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT105